Drug Trial Radar · NCT03890666
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
333
Actual
Start
Oct 26, 2020
Primary completion
Oct 4, 2021
Study completion Oct 4, 2021
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Mar 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health platform (DHP) (Cloud solution), and dashboard, to optimize outcomes in participants at least 13 years of age or older with asthma. The study will consist of a screening visit, a 12-week open-label treatment period, and a follow-up telephone call (2 weeks following treatment completion). Participants with suboptimal asthma control will be enrolled in the study and randomized in a 1:1 ratio to 1 of 2 parallel groups stratified by investigational center: DS group participants utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard, and CC group participants who will be treated with their standard of care albuterol-administering rescue inhalers and will not use the DS during the treatment period.
Conditions
- Asthma
Interventions
Albuterol eMDPI DSDrug
Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices: * Device 1: Albuterol eMDPI * Device 2: Albuterol eMDPI Patient-facing smart device application (App) * Device 3: DHP Cloud solution) * Device 4: Provider-facing dashboard (dashboard)
albuterolDrug
Standard of care albuterol-administering rescue inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Meaningful Asthma Improvement at the End of 12-Week Treatment PeriodTime frame: Baseline to Week 12
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 14232
Birmingham, Alabama
Teva Investigational Site 14302
Los Angeles, California
Teva Investigational Site 14301
Stockton, California
Teva Investigational Site 14236
Colorado Springs, Colorado
Teva Investigational Site 14198
Denver, Colorado
Teva Investigational Site 14220
New Haven, Connecticut
Teva Investigational Site 14197
Aventura, Florida
Teva Investigational Site 14306
Miami, Florida
Teva Investigational Site 14215
Sarasota, Florida
Teva Investigational Site 14304
Albany, Georgia
Teva Investigational Site 14195
Savannah, Georgia
Teva Investigational Site 14217
Evanston, Illinois
Teva Investigational Site 14218
Springfield, Illinois
Teva Investigational Site 14305
Louisville, Kentucky
Teva Investigational Site 14191
Owensboro, Kentucky
Teva Investigational Site 14233
Ann Arbor, Michigan
Teva Investigational Site 14207
Bellevue, Nebraska
Teva Investigational Site 14221
New York, New York
Teva Investigational Site 14234
Chapel Hill, North Carolina
Teva Investigational Site 14187
Cincinnati, Ohio
Teva Investigational Site 14210
Philadelphia, Pennsylvania
Teva Investigational Site 14208
Pittsburgh, Pennsylvania
Teva Investigational Site 14200
Providence, Rhode Island
Teva Investigational Site 14300
Charleston, South Carolina
Teva Investigational Site 14196
Greenville, South Carolina
Teva Investigational Site 14188
San Antonio, Texas
Teva Investigational Site 14192
San Antonio, Texas
Teva Investigational Site 14189
San Antonio, Texas
Teva Investigational Site 14190
Greenfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.